Cardiogenic shock: Basics and clinical considerations

International Journal of Cardiology

Volumn 123, Issue 3, 2008, Pages 221-228

  Gowda, Ramesh M ^a,b   Fox, John T ^a,b   Khan, Ijaz A ^a,b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Cardiogenic shock; Heart failure; Intra atrial balloon pump; Myocardial infarction

Indexed keywords

ABCIXIMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; COMPLEMENT COMPONENT C5 INHIBITOR; CONTRAST MEDIUM; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INOTROPIC AGENT; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PEXELIZUMAB; PHOSPHODIESTERASE INHIBITOR;

AORTA BALLOON; ASSISTED CIRCULATION; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CLINICAL FEATURE; COMPLEMENT SYSTEM; CONGESTIVE HEART FAILURE; CORONARY REPERFUSION; DEVICE THERAPY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG POTENTIATION; ELECTROCARDIOGRAM; ENZYME RELEASE; FLUID RESUSCITATION; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PERFUSION; HEART PRELOAD; HEART RATE; HUMAN; HYPOTENSION; INCIDENCE; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; STENT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UPREGULATION; URINE VOLUME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; COMBINED MODALITY THERAPY; COMPLEMENT C5; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; INCIDENCE; INTRA-AORTIC BALLOON PUMPING; MALE; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SHOCK, CARDIOGENIC; SURVIVAL ANALYSIS;

EID: 37449019886     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.03.099     Document Type: Review

References (70)

1. Nieminen M.S., Bohm C., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
2. Goldberg R.J., Samad N.A., Yarzdbski J., et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 340 (1999) 1162-1168
3. Babaev A., Frederick P.D., Pasta D.J., et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 294 (2005) 448-454
4. Moscucci M, Bates ER. Cardiogenic shock, Cardiol Clin 13 (1995) 391-406
5. Herrick J.B. Clinical features of sudden obstruction of the coronary arteries. JAMA 39 (1912) 2015-2020
6. Griffith G.C., Wallace W.B., Cochran B., et al. The treatment of shock associated with myocardial infarction. Circulation 9 (1954) 527
7. Julian D.G. The history of coronary care units. Br Heart J 57 (1987) 497-502
8. Monlopoulos S.D., Tiopez S., and Kolff W.J. Diastolic balloon pumping in the aorta: a mechanical assistance to the failing circulation. Am Heart J 63 (1962) 669-675
9. Killip III T., and Kimball J.T. Treatment of myocardial infarction in a coronary care unit: a two year history experience with 250 patients. Am J Cardiol 20 (1967) 457-464
10. Swan H.J., Ganz W., Forrestor J., et al. Catheterization of the heart in man with the use of a flow-directed balloon-tipped catheter. N Engl J Med 283 (1970) 447-451
11. Dunkman W.B., Leinbach R.C., Buckley M.J., et al. Clinical and hemodynamic results of intra-aortic balloon pumping and surgery for cardiogenic shock. Circulation 46 (1972) 465-477
12. O'Neill W.W., Erbel R., and Lsufer N. Coronary angioplasty therapy of cardiogenic shock complicating acute myocardial infarction. Circulation 72 Suppl II (1985) 309
13. Hasdai D., Topol E.J., Califf R.M., et al. Cardiogenic shock complicating acute coronary syndromes. Lancet 356 (2000) 749-756
14. Scheidt S., Ascheim R., and Killip T. Shock after acute myocardial infarction. Am J Cardiol 26 (1970) 556
15. Quigley R.L., Milano C.A.D., Smith L.R., et al. Prognosis and management of anterolateral myocardial infarction in patients with severe left main disease and cardiogenic shock: the left main shock syndrome. Circulation 88 (1993) 65-70
16. Hochman J.S., Boland J., Sleeper L.A., et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an International Registry. SHOCK Registry Investigators. Circulation 91 (1995) 873-881
17. Widimsky P., George P., Cervenka V., et al. Severe diffuse hypokinesis of the remote myocardium. The main cause of cardiogenic shock? An echocardiographic study of 75 patients with extremely large myocardial infarctions. Cor Vasa 30 (1988) 27-34
18. Olivetti G., Quaini F., Sala R., et al. Acute myocardial infarction in humans is associated with activation of programmed myocytic cell death in the surviving portion of the heart. J Mol Cell Cardiol 28 (1994) 1016-1025
19. Gowda R.M., Khan I.A., Vasavada B.C., et al. Reversible myocardial dysfunction: basics and evaluation. Int J Cardiol 97 (2004) 349-353
20. Lupi-Herrera E., Lasses L.A., Cosio-Aranda J., et al. Acute right ventricular infarction: clinical spectrum, results of reperfusion therapy and short-term prognosis. Coronary Artery Disease 13 (2002) 57-64
21. Bartling B., Holtz J., and Darmer D. contribution of myocyte apoptosis to myocardial infarction. Basic Res Cardiol 93 (1998) 71-84
22. Hasdai D., Califf R.M., Thompson T.D., et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 35 (2000) 136-143
23. Holmes Jr. D.R., Bates E.R., Kleiman N.S., et al. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience: the GUSTO-I Investigators. global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J AM Coll Cardiol 26 (1995) 668-674
24. Cotter G., Moshkovitz Y., Kaluski E., et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 5 (2003) 443-451
25. Ellis T.C., Lev E., Yazbek N.F., and Kleiman N.S. Therapeutic strategies for cardiogenic shock. Curr Treatment Options Cardiovasc Med 8 (2006) 79-94
26. Khan I.A., and Gowda R.M. Clinical perspectives and therapeutics of thrombolysis. Int J Cardiol 9 (2003) 115-127
27. Kennedy J.W., Gensini G.G., Timmis G.C., et al. Acute myocardial infarction related with intracoronary streptokinase: a report of the Society for Cardiac Angiography. Am J Cardiol 55 (1985) 871-877
28. Prewitt R.M., Gu S., Garber P.J., et al. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 20 (1992) 1626-1633
29. Garber P.J., Mathieson A.l., Ducas J., et al. Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration. Can J Cardiol 11 (1995) 30-36
30. Ammann P., Straumann E., Naegeli B., et al. Long-term results after acute percutaneous transluminal coronary angioplasty in acute myocardial infarction and cardiogenic shock. Int J Cardiol 82 (2002) 127-131
31. Taghizadeh B., Chieu J.A., Papaleo R., et al. AngioJet thrombectomy and stenting for reperfusion in acute MI complicated with cardiogenic shock. Catheter Cardiovasc Interv 57 (2002) 79-84
32. Giri S., Mitchel J., Azar R.R., et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 89 (2002) 126-131
33. Wong S.C., Sleeper L.A., Monrad E.S., et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. J Am Coll Cardiol 38 (2001) 1395-1401
34. Hsu R.B., Chien C.Y., Wang S.S., et al. Survival after early surgical revascularization in patients with both acute myocardial infarction and cardiogenic shock. J Formos Med Assoc 100 (2001) 725-728
35. Hochman J.S., Sleeper L.A., White H.D., et al. Should we emergently revascularize occluded coronaries for cardiogenic shock. One-year survival following early revascularization for cardiogenic shock. JAMA 285 (2001) 190-192
36. Prewitt R.M., Gu S., Schick U., et al. Intra-aortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 23 (1994) 794-798
37. Scheidt S., Wilner G., Mueller H., et al. Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial. N Engl J Med 288 (1973) 979-984
38. Willerson J.T., Curry G.C., Watson J.T., et al. Intraaortic balloon counterpulsation in patients with cardiogenic shock medically refractory left ventricular failure and/or recurrent ventricular tachycardia. Am J Med 58 (1975) 183-191
39. Haemeijer F., Laird J.D., Haalebos M.M., et al. Effectiveness of intraaortic balloon pumping without cardiac surgery for patients with severe heart failure secondary to a recent myocardial infarction. Am J Cardiol 40 (1977) 951-956
40. Gurbel P.A., Anderson R.D., MacCord C.S., et al. Arterial diastolic pressure augmentation by intraaortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. Circulation 89 (1994) 361-365
41. Kovack P.J., Rasak M.A., Bates E.R., et al. Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J Am Coll Cardiol 29 (1997) 1454-1458
42. Sanborn T., Sleeper L.A., Bates E.R., et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol 36 3 Suppl A (2000) 1123-1129
43. Barron H.V., Every N.R., Parsons L.S., et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart j 141 (2001) 933-939
44. Ferguson J.J., Cohen M., Freedman Jr. R.J., et al. The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. J Am Coll Cardiol 38 (2001) 1456-1462
45. Williams M., Oz M., and Mancini D. Cardiac assist devices for end-stage heart failure. Heart Dis 3 (2001) 109-115
46. Tsai F.C., Marelli D., Laks H., et al. Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. Am J Transplant 2 (2002) 646-651
47. Kurusz M, Zwischenberger JB, Percutaneous cardiopulmonary bypass for cardiac emergencies. Perfusion 17 (2002) 269-277
48. Flesch M., Kilter H., Cremers B., et al. Acute effects of nitricoxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther 28 (1997) 1340-1349
49. Mohan P., Brutsaert D.L., Paulus W.J., et al. Myocardial contractile response to nitric oxide and cGMP. Circulation 93 (1996) 1223-1229
50. Zhang Y., Bissing J.W., Xu L., et al. Nitric oxide synthase inhibitors decrease coronary sinus-free radical concentration and ameliorate myocardial stunning in an ischemia-reperfusion model. J Am Coll Cardiol 38 (2001) 546-554
51. Ziolo M.T., Katoh H., and Bers D.M. Expression of inducible nitric oxide synthase depresses ß-adrenergic-stimulated calcium release from the sarcoplasmic reticulum in intact ventricular myocytes. Circulation 104 (2001) 2961-2966
52. Balligand J.L., and Cannon P.J. Nitric oxide synthases and cardiac muscle: autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 17 (1997) 1846-1858
53. Sanchez de Miguel L., Arriero M.M., Farre J., et al. Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes: expression of the nitric oxide synthase isoforms. J Am Coll Cardiol 39 (2002) 818-825
54. Sam F., Sawyer D.B., Xie Z., et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death later after myocardial infarction. Circ Res 89 (2001) 351-356
55. Feng O., Lu X., Jones D.L., et al. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104 (2001) 700-704
56. Cotter G., Kaluski E., Blatt A., et al. L-NMMA (a nitric oxyde synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 101 (2000) 1358-1361
57. Cotter G., Kaluski E., Blatt A., et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 24 (2003) 1287-1295
58. Geppert A., Steiner A., Zorn G., et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 30 (2002) 1987-1994
59. Frangogiannis N.G., Smith C.W., and Antman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 53 (2002) 31-47
60. Pudil R., Krejsek J., Pidrman V., et al. Inflammatory response to acute myocardial infarction complicated by cardiogenic shock. Acta Medica 44 (2001) 149-151
61. Riese U., Brenner S., Docke W.D., et al. catecholamines induce IL-10-release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T cells. Mol Cell Biochem 212 (2000) 45-50
62. Geppert A., and Huber K. Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the Intensive Care Unit. Curr Opin Crit Care 10 (2004) 347-353
63. Hill J.H., and Ward P.A. The phlogistic role of C3 Leukotactic fragments in myocardial infarcts of rats. J Exp Med 133 (1971) 885-900
64. Pinckard R.N., Olson M.S., Giclas P.C., et al. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 56 (1975) 740-750
65. Rossen R.D., Michael L.H., Hawkins H.K., et al. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. Circ Res 75 (1994) 546-555
66. Dreyer W.J., Michael L.H., Nguyen T., et al. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res 71 (1992) 1518-1524
67. Patel mitral regurgitation, and Granger C.B. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. Drugs Today 41 (2005 Mar) 165-170
68. Vakeva A.P., Agah A., Rollins S.A., et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97 (1998) 2259-2267
69. Granger C.B., Mahaffey K.W., and Weaver W.D. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial Infarction treated with Angioplasty (COMMA) trial. Circulation 108 (2003) 1184-1190
70. Armstrong P.W., Adams P.X., Al-Khalidi H.R., et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 149 (2005) 402-407